Araştırma Makalesi
Yıl 2020,
, 44 - 48, 20.05.2020
Öz
Kaynakça
- 1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J [Internet]. 2020 Jan 14;41(3):407–77. 2. Solymoss BC, Bourassa MG, Lespérance J, Levesque S, Marcil M, Varga S, et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis [Internet]. 2003 May;14(3):207–12. 3. Lipsy RJ. Introduction. J Manag Care Pharm [Internet]. 2003 Jan;9(1 Supp A):2–5. 4. Yavuz B, Kabakci G, Aksoy H, Tulumen E, Deveci OS, Aytemir K, et al. Determining the relationship between metabolic syndrome score and angiographic severity of coronary artery disease. Int J Clin Pract [Internet]. 2008 Feb 7;62(5):717–22. 5. Juarez-Orozco LE, Saraste A, Capodanno D, Prescott E, Ballo H, Bax JJ, et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. Eur Hear J - Cardiovasc Imaging [Internet]. 2019 Apr 14; 6. Foldyna B, Udelson JE, Karády J, Banerji D, Lu MT, Mayrhofer T, et al. Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. Eur Heart J Cardiovasc Imaging [Internet]. 2019 May 1;20(5):574–81.
The relationship between metabolic syndrome score and cardiac ischemia detected by noninvasive cardiac tests
Öz
Objective: Cardiovascular disease is the still leading cause of mortality and morbidity. Non-invasive cardiac tests are using for diagnosing CAD in symptomatic patients in clinical practice. Metabolic syndrome (MS) is a well-known risk factor for coronary artery disease (CAD). In this study we aimed to investigate the relationship between metabolic syndrome score and results of non-invasive cardiac tests.
Method: The total number of 329 patients who admitted with chest pain to cardiology department were included in the study. MS score based on National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria which ranged between zero and five were calculated for each subject. After physical examination and routine laboratory tests patients with high pretest probability underwent non-invasive cardiac tests (treadmill test and myocardial perfusion scintigraphy)to rule out chest pain from non-cardiac reasons. The results of non-invasive tests evaluated with metabolic risk score of patients.
Results: The study population consisted of 192 (58.4%) male, and 137 (41.6%) female subjects. The mean age was 68.3 ±9 in patients without ischemia and 69.4 ±7.2 (p=N/S) patients with ischemia. Metabolic score was 1.8±1.1 in patients without ischemia 2.67±1.3 in patients with ischemia (p=<0.01) Patients with coronary ischemia had higher metabolic syndrome score than patients without ischemia (p<0.01).
Conclusions: In this study, we showed that patients with high metabolic risk score. In this study, non-invasive cardiac tests performed in patients with high metabolic risk scores showed more ischemia. Metabolic risk score should be considered in the evaluation of patients for coronary artery disease.
Anahtar Kelimeler
Kaynakça
- 1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J [Internet]. 2020 Jan 14;41(3):407–77. 2. Solymoss BC, Bourassa MG, Lespérance J, Levesque S, Marcil M, Varga S, et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis [Internet]. 2003 May;14(3):207–12. 3. Lipsy RJ. Introduction. J Manag Care Pharm [Internet]. 2003 Jan;9(1 Supp A):2–5. 4. Yavuz B, Kabakci G, Aksoy H, Tulumen E, Deveci OS, Aytemir K, et al. Determining the relationship between metabolic syndrome score and angiographic severity of coronary artery disease. Int J Clin Pract [Internet]. 2008 Feb 7;62(5):717–22. 5. Juarez-Orozco LE, Saraste A, Capodanno D, Prescott E, Ballo H, Bax JJ, et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. Eur Hear J - Cardiovasc Imaging [Internet]. 2019 Apr 14; 6. Foldyna B, Udelson JE, Karády J, Banerji D, Lu MT, Mayrhofer T, et al. Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. Eur Heart J Cardiovasc Imaging [Internet]. 2019 May 1;20(5):574–81.
Toplam 1 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Basic Science Research Makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 20 Mayıs 2020 |
| Kabul Tarihi | 13 Mayıs 2020 |
| Yayımlandığı Sayı | Yıl 2020 |